Calixa Therapeutics, Inc.

Calixa Therapeutics, Inc.

Calixa Therapeutics, Inc.

Date Founded



12481 High Bluff Drive,Suite 150,San Diego, CA 92130

Type of Company




Company Description

Calixa Therapeutics, Inc. develops and commercializes hospital-based anti-infective therapies. The company was founded by Eckard Weber and James Ge in 2007 and is headquartered in San Diego, CA.

Executives & Employees





Board of Directors

President at Canaan Management, Inc.

Founder at Frazier Healthcare Partners

Co-Founder at QuatRx Pharmaceuticals Co.

Paths to Calixa Therapeutics, Inc.
Potential Connections via
Relationship Science
Calixa Therapeutics, Inc.
Recent Transactions
Details Hidden

Cubist Pharmaceuticals LLC purchases Calixa Therapeutics, Inc.

Details Hidden

Senior Advisor at Cenova Ventures

Details Hidden

Frazier Management provides venture capital to invests in developing and commercializing novel therapeutics and and growth equity capital invests in healthcare services, pharmaceutical services, medical products, and related sectors. with primary focus on The firm invests across all stages of development.The firm's venture capital strategy focuses on all stages of biopharmaceutical and medical device companies including seed, early, mid, late, PIPEs and public. Their biopharmaceutical investment strategy focuses on companies that are developing novel therapeutics. They seek to identify early-stage companies that can use the firm's capital to move their products through clinical trials to achieve clinical proof of concept. Frazier works with a variety of types of companies including concept-stage, preclinical drug leads, clinical candidates and marketed products. The therapeutic modality also varies from small molecule to biologic. Frazier's medical device strategy focuses on companies with innovative technologies that address significant unmet clinical needs in large market segments.When considering a venture capital investment, Frazier looks for companies with exceptional management teams and capital efficient business models. They seek companies that are building their product portfolio through (1) novel targets or device-based approaches to existing targets which are significantly differentiated (2) paradigm-shifting therapeutic or device platforms to develop multiple products or (3) repositioning or in-licensing of existing drugs which are known to be safe and may have applications in other indications. The firm prefers to invest in products with large addressable markets in therapeutic areas that are supported by healthcare professionals who are open to innovative therapies. Frazier looks for therapeutic drug products that are close to or already in the clinic. They seek medical devices with moderate development risk that can rapidly generate clinical proof of principle and/or can be launched commercially within a reasonable time frame. Companies should have a clear path to regulatory approval and positive reimbursement decisions.Frazier also seeks to invest in cash-generating, growth-oriented healthcare companies. Types of investments include: acquisitions, recapitalizations, buyouts, build-ups and growth capital. They focus on the healthcare services, medical devices and supplies, specialty pharmaceutical and information technology-enabled services sectors. Investments typically range from $15 million to $50 million. The firm looks for companies with experienced management teams, attractive free cash flow margins, meaningful organic growth with the potential for consolidation opportunities, leading and defensible market positions, a predictable reimbursement environment and demonstrable customer loyalty.

Details Hidden

Canaan Management focuses on investments primarily in the technology and healthcare sectors. In the technology sector, the firm focuses on digital media, communications, mobility, enterprise software and clean technology. Within the healthcare sector, Canaan Partners focuses on investments in biopharmaceuticals, medical devices and diagnostics. Canaan Partners also invests technology-based Indian companies in the following sectors: consumer Internet, digital media, mobile and enterprise and managed services. In Israel, the firm seeks to invest in the development of early-stage companies in the following areas: (1) consumer Internet and digital media (2) communications infrastructure (3) enterprise software (4) clean technology and (5) medical device technologies.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Calixa Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Calixa Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Calixa Therapeutics, Inc..